Udenafil is the fourth in a class of drugs targeting the inhibition of the enzyme phosphodiesterase 5 (PDE5) for the treatment of erectile dysfunction. Inhibition of PDE5 results in the increase in endogenous cyclic guanosine monophosphate (cGMP) concentrations in the penile corpus cavernosum. cGMP induces smooth muscle cell relaxation and subsequent increased blood flow leading to a sustainable erection. Udenafil is a potent antagonist of human PDE5 with an IC50 of 8.25nM and a comparable selectivity profile as sildenafil for the other PDEs. Unlike tadalafil, it does not inhibit PDE11, which has been implicated in myalgia and testicular toxicity. Furthermore, udenafil produced up to a 91% vaginal penetration success rate and up to a 67% intercourse completion rate compared to a 29% completion rate by placebo. Overall patient satisfaction, measured by a standard global assessment question, was 86% compared to only 26% in the placebo group. The most frequently recorded adverse events were mild-to-moderate facial flushing and headache.
Udenafil is an inhibitor of phosphodiesterase 5 (PDE5). In vivo, udenafil (1 and 5 mg/kg) increases lung cGMP levels, attenuates the development of compensatory right ventricular hypertrophy, and reduces pulmonary arterial wall thickening in a rat model of monocrotaline-induced pulmonary hypertension. It increases creatine clearance and decreases blood urea nitrogen (BUN) and serum malondialdehyde (MDA) levels in a rat model of renal ischemia-reperfusion injury. Udenafil (0.3 and 10 mg/kg) induces penile erections in conscious rabbits and in rabbits with acute spinal cord injury.
Muna da masana'antu masu inganci da yawa tare da haɗin gwiwa mai zurfi, wanda zai iya ba ku samfuran inganci da farashin gasa. Kuma muna iya ba da rangwamen kuɗi don sayayya mai yawa. Kuma muna ba da haɗin kai tare da ƙwararrun kamfanoni masu jigilar kaya, za su iya isar da samfuran cikin aminci da kwanciyar hankali ga hannunku. Lokacin bayarwa shine kimanin kwanaki 3-20 bayan tabbatar da biyan kuɗi.
Product Name: | Udenafil |
Synonyms: | 5-[2-propyloxy-5-(2-(1-Methylpyrrolidin-2-yl)ethylaMinosulphonyl)phenyl]-1-Methyl-3-propyl-6,7-dihydro-1H-pyrazolo(4,3-d)pyriMidin-7-one;5-[2-propyloxy-5-[2-(1-Methyl-2-pyrrolidinyl)ethylaMinosulfonyl]phenyl]-1-Methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyriMidine-7-one;Zydena;Udenafil(DA 8159,Zydena);BenzenesulfonaMide,3-(6,7-dihydro-1-Methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyriMidin-5-yl)-N-[2-(1-Methyl-2-pyrrolidinyl)ethyl]-4-propoxy-;Udenafil, DA 8159;CS-1353;Udenafil, >=98% |
CAS: | 268203-93-6 |
MF: | C25H36N6O4S |
MW: | 516.66 |
EINECS: | 251-228-4 |
Product Categories: | Intermediates & Fine Chemicals;Pharmaceuticals |
Mol File: | 268203-93-6.mol |
![]() |
Udenafil Chemical Properties |
Wurin narkewa | 152-159°C |
Wurin tafasa | 697.0±65.0 °C(Predicted) |
yawa | 1.35 |
yanayin ajiya. | under inert gas (nitrogen or Argon) at 2-8°C |
narkewa | Chloroform (Slightly), Methanol (Sparingly) |
tsari | Solid |
pka | 11.07±0.50(Predicted) |
launi | White to Pale Beige |
1. Shin ku masana'anta ne ko kamfani na kasuwanci?
Mu kamfani ne mai haɗa masana'antu da kasuwanci, samar da sabis na tsayawa ɗaya. Ana iya karɓar OEM.
2. Kuna samar da samfurori? Yana da kyauta ko kari?
Samfuran kyauta. Ana buƙatar biyan kuɗin jigilar samfurin ta gefen ku.
3. Kuna da wasu takaddun shaida masu alaƙa da kula da inganci?
ISO 9001: 2008 takardar shaida don tabbatar da inganci.
4. Menene zan bayar don samun zance?
Pls sanar da mu nau'in samfurin wanda kuke buƙata, adadin oda, adireshi da takamaiman buƙatu. Za a yi zance don bayanin ku cikin lokaci.
5. Wane irin hanyar biyan kuɗi kuka fi so? Wane irin sharuɗɗan ne ake karɓa?
Sharuɗɗan Isar da Karɓa: FOB, CFR, CIF, EXW;
Kudin Biyan Da Aka Karɓa: USD;
Nau'in Biyan Da Aka Karɓa: T/T, Western Union; Paypal, Tabbacin Kasuwanci.
Harshe Ana Magana: Turanci.
Rukunin samfuran